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Sickle cell disease is the most prevalent monogenic disor-
der worldwide resulting from single DNA mutation in
beta globin gene. The mapping on the pattern of its distri-
bution in India has been studied to a great extent. How-
ever paucity of adequate data throughout the country
regarding the clinical manifestations, natural history of the
disorder and correlation with genotype and phenotype of
the SCD cases is observed. This communication will focus
on following aspects: (i) prevention and control of the
SCD in India. (ii) the good clinical management with par-
ticular reference to pain during the vaso-occlussive crisis.
(iii) neonatal screening and genetic counseling in SCD in
tribals of India.
Between August 2009 and July 2010, 1668 newborns
were enrolled and screened for SCD in Kalahandi district
of Odisha. An average incidence of 17.62% of sickle cell
trait (HbAS) was recorded for the area with the highest
incidence observed in the tribal dominated part (19.03%).
The data till date reveals a striking fact that more than
20 per thousand live births in the district are born with
the disease. All the 34 cases of SCA detected were con-
firmed by parents testing, of which confirmation of 4 cases
of compound heterozygosity for HbS and b-thalassaemia
is an interesting finding.
For pain management with an informed approved
consent in 15 patients treated at Apollo Hospital,
Bhubaneswar we have given nitric oxide inhalation at
80 ppm for 6-12 hrs and 90% of patients responded
well, pain score being relieved significantly >60%. In
2 patients there was recurrence of pain on 2nd day and
they were given again the same therapy. Another
1 patient did not respond very well to pain. On investiga-
tion she was found to have superficial vein thrombosis of
left hand.
This NBS programme design provides scope for catering
the benefit in rural areas and follow up for newborns. It
also stresses on the acute need of such kind of extensive
reach-out programme for early and confirmed detection
of SCD in other places of the country. This will ultimately
reduce the child mortality and morbidity in SCD. Nitric
Oxide inhalation for pain relief in VOC of SCA is a very
effective and less expensive method.
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